Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anzutresgene autoleucel
- Development stage
- Phase 3
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anzutresgene autoleucel is a genetically modified autologous T cell therapy classified as a T-cell receptor (TCR) gene therapy. It uses a patient's own T cells, which are harvested and genetically engineered to express a specific T-cell receptor targeting a cancer-associated antigen. This process enables the infused T cells to recognize cancer cells expressing that antigen and attack them, functioning as a form of targeted cellular immunotherapy. Specific information on the targeted antigen, mechanism, developer, indications, and approval status for anzutresgene autoleucel is not found in the provided search results; however, the drug has a validated record in the FDA UNII database, indicating it is recognized as a distinct pharmaceutical entity[8].
- Brand names
- ACTengine
- Other names
- ACTengine IMA203 TCR-TACTengine IMA203 cell therapyImmatics ACTengine IMA203
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on anzutresgene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anzutresgene autoleucel.